From Free Rider to Innovator: The Rise of China’s Drug Development

Panle Barwick (), Hongyuan Xia and Tianli Xia

No 34977, NBER Working Papers from National Bureau of Economic Research, Inc

Abstract: In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the U.S. in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug development supply chain: global data on scientific publications, clinical trials, and drug development milestones, combined with data on drug sales and government policies in China over the same period. We provide evidence that China’s National Reimbursement Drug List (NRDL) reform dramatically expanded the effective market size for innovative drugs and contributed to the country’s rise in biomedical innovation. We document a sharp increase in both the quantity (86%) and novelty of Chinese drug trials post-reform relative to U.S. trials, with similar patterns relative to Europe. This growth is concentrated in reform-exposed disease categories, first- or best-in-class drugs, and domestic firms. A decomposition exercise reveals that the NRDL reform accounts for 59% of the growth in oncology trial activity, comparable to the combined contribution of upstream knowledge accumulation and talent flows (21%) and venture capital investment (19%), while other government policies play a minor role. Finally, dynamic gains from induced innovation exceed the reform’s static gains in consumer access to innovative drugs by threefold, underscoring the importance of accounting for the reform’s long-run effects on innovation incentives beyond near-term improvements in drug affordability.

JEL-codes: I18 L65 O31 O38 (search for similar items in EconPapers)
Date: 2026-03
New Economics Papers: this item is included in nep-bec, nep-cna, nep-hea, nep-ind, nep-ino and nep-tid
Note: EH IO PR
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.nber.org/papers/w34977.pdf (application/pdf)
Access to the full text is generally limited to series subscribers, however if the top level domain of the client browser is in a developing country or transition economy free access is provided. More information about subscriptions and free access is available at http://www.nber.org/wwphelp.html. Free access is also available to older working papers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nbr:nberwo:34977

Ordering information: This working paper can be ordered from
http://www.nber.org/papers/w34977
The price is Paper copy available by mail.

Access Statistics for this paper

More papers in NBER Working Papers from National Bureau of Economic Research, Inc National Bureau of Economic Research, 1050 Massachusetts Avenue Cambridge, MA 02138, U.S.A.. Contact information at EDIRC.
Bibliographic data for series maintained by ().